Japanese Society of Medical Oncology

Japanese Society of Medical Oncology
Name	Japanese Society of Medical Oncology
Formation	1993
Type	Learned society
Headquarters	Tokyo
Region served	Japan
Leader title	President

Japanese Society of Medical Oncology is a professional association focused on clinical oncology, cancer therapeutics, and translational research in Japan, engaging oncologists, researchers, and allied institutions. The society interfaces with national agencies, academic hospitals, and pharmaceutical firms to shape cancer care, clinical trials, and policy in collaboration with domestic and international partners. It organizes annual meetings, issues clinical practice guidelines, and publishes scholarly journals to disseminate advances in oncology research and treatment.

History

The society emerged in the early 1990s amid changing cancer care landscapes influenced by institutions such as National Cancer Center Hospital (Japan), University of Tokyo Hospital, Osaka University Hospital, Kyoto University Hospital, and policy shifts stemming from the Ministry of Health, Labour and Welfare (Japan). Founding members included clinicians affiliated with Keio University School of Medicine, Tohoku University Graduate School of Medicine, Hokkaido University Hospital, Nagoya University Hospital, and Kobe University Hospital, drawing on international models like the American Society of Clinical Oncology, European Society for Medical Oncology, and National Comprehensive Cancer Network. Early initiatives connected the society with research networks such as Japan Clinical Oncology Group and regulatory frameworks like the Pharmaceuticals and Medical Devices Agency (Japan), while collaborating with patient advocacy groups modeled after Cancer Research UK and Susan G. Komen for the Cure.

Mission and Objectives

The society's objectives align with standards set by bodies including World Health Organization, International Agency for Research on Cancer, Organisation for Economic Co-operation and Development, and regional counterparts such as Asia-Pacific Society of Clinical Oncology. Core aims include promoting evidence-based oncology aligned with guidelines from National Institute for Health and Care Excellence, fostering translational science exemplified by partnerships with Riken, supporting clinical trial infrastructure like Japan Medical Association-affiliated networks, and improving survivorship care inspired by programs at Dana-Farber Cancer Institute and MD Anderson Cancer Center.

Membership and Organization

Membership comprises clinicians and scientists from institutions such as Fujita Health University, St. Luke's International Hospital (Tokyo), Saitama Medical University, Jichi Medical University, and research institutes like Aichi Cancer Center. The governance structure mirrors models used by American Association for Cancer Research and features committees on ethics, guidelines, education, and clinical trials with liaisons to agencies such as Japan Agency for Medical Research and Development and professional groups like Japan Surgical Society, Japanese Society of Pathology, and Japanese Society of Radiation Oncology. Leadership roles are typically held by faculty from universities including Keio University, Osaka City University, Kumamoto University, Niigata University Hospital, and Kanazawa University.

Conferences and Education

Annual meetings bring together experts from Harvard Medical School, Johns Hopkins School of Medicine, Memorial Sloan Kettering Cancer Center, The University of Texas MD Anderson Cancer Center, Seoul National University College of Medicine, and National Taiwan University Hospital alongside domestic centers such as Kobe City Medical Center General Hospital and Shinshu University School of Medicine. Educational activities include workshops on clinical trial design referencing standards from International Committee of Medical Journal Editors, courses on precision medicine drawing on databases like The Cancer Genome Atlas, and symposia featuring speakers from European Organisation for Research and Treatment of Cancer and Translational Research Oncology Society.

Research and Guidelines

The society contributes to guideline development in areas such as chemotherapy, targeted therapy, and immunotherapy, aligning with standards from European Society for Medical Oncology and evidence syntheses comparable to Cochrane Collaboration. It supports multicenter clinical trials coordinated with groups like Japan Clinical Oncology Group, engages with biomarker validation efforts similar to projects at Broad Institute, and promotes real-world data studies referencing registries like Surveillance, Epidemiology, and End Results Program. Guideline panels often include experts from Japanese Breast Cancer Society, Japanese Lung Cancer Society, Japanese Gastric Cancer Association, Japanese Society of Hepato-Biliary-Pancreatic Surgery, and Japanese Urological Association.

Publications

The society publishes peer-reviewed material and position statements in journals comparable to Journal of Clinical Oncology, The Lancet Oncology, and regional titles such as Asia-Pacific Journal of Clinical Oncology. Contributors include clinicians from Tokyo Medical University, Showa University School of Medicine, Chiba University Graduate School of Medicine, and research scientists affiliated with Osaka Prefectural Medical Center for Cancer and Cardiovascular Diseases. Publication topics cover clinical trials, practice guidelines, pharmacoeconomics informed by analyses like those in Health Technology Assessment International, and registry-based epidemiology akin to studies published by International Journal of Cancer.

Collaborations and International Relations

International partnerships involve exchanges with organizations such as American Society of Clinical Oncology, European Society for Medical Oncology, ASCO International, Asia-Pacific Clinical Oncology Group, and academic collaborations with Imperial College London, University of Cambridge, Stanford University School of Medicine, Peking University Health Science Center, and Seoul National University Hospital. Collaborative projects engage regulatory and funding agencies like Pharmaceuticals and Medical Devices Agency (Japan), Japan Agency for Medical Research and Development, Bill & Melinda Gates Foundation, and global health initiatives associated with World Health Organization and Union for International Cancer Control.

Category:Medical associations based in Japan Category:Oncology organizations